Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features SAN CARLOS
(Financial Post, 2025-12-07T23:09:18Z)